Anticancer Drugs Practice Questions

Q: Estramustine is a combination of which two drugs?

Estradiol + Normustine. ***Estradiol + Normustine*** - **Estramustine** is a **chemotherapeutic agent** used in the treatment of **prostate cancer**. - It is a **conjugate molecule** combining **estradiol-17β** (a synthetic estrogen) with **normustine** (nor-mechlorethamine, a nitrogen mustard derivative). - The estrogen component targets the hormone-responsive prostate tissue, while the alkylating agent provides cytotoxic effects. *Estradiol + mechlorethamine* - While **normustine** (nor-mechlorethamine) is chemically related to **mechlorethamine**, estramustine specifically contains **normustine**, not mechlorethamine itself. - Normustine is a demethylated derivative of mechlorethamine, making this option close but technically incorrect. *Etoposide + Cisplatin* - **Etoposide** and **Cisplatin** are distinct chemotherapeutic agents often used in combination for various cancers, including **lung cancer** and **germ cell tumors**. - They do not form a single molecular conjugate like estramustine. *Tamoxifen + Letrozole* - **Tamoxifen** and **letrozole** are **endocrine therapies** used primarily in **breast cancer**. - Tamoxifen is a **selective estrogen receptor modulator (SERM)**, and letrozole is an **aromatase inhibitor**; they are not combined to form a single drug molecule like estramustine.

Q: Anticancer drug causing syndrome of inappropriate antidiuretic hormone secretion (SIADH) as an adverse effect is:

Vincristine. ***Vincristine*** - Vincristine is a **vinca alkaloid** (microtubule inhibitor) that is **classically associated with SIADH** as a well-documented adverse effect. - The mechanism involves **neurotoxicity** affecting the hypothalamus or posterior pituitary, leading to **excessive ADH secretion**. - This results in **hyponatremia** with concentrated urine and is a high-yield association for medical exams. *Paclitaxel* - Paclitaxel is a **taxane** (microtubule stabilizer) with different adverse effect profile. - Primary adverse effects include **myelosuppression**, peripheral neuropathy, and hypersensitivity reactions. - **SIADH is not a characteristic adverse effect** of paclitaxel. *Dacarbazine* - Dacarbazine is an **alkylating agent** used primarily in melanoma and Hodgkin lymphoma. - Main adverse effects are **myelosuppression**, severe nausea/vomiting, and flu-like symptoms. - **SIADH is not associated** with dacarbazine use. *Cyclophosphamide* - Cyclophosphamide is an **alkylating agent** with well-known adverse effects including hemorrhagic cystitis and myelosuppression. - While cyclophosphamide can rarely cause SIADH, it is **not the classic association** tested in exams. - **Vincristine remains the prototype drug** for anticancer drug-induced SIADH in medical education.

Q: A patient with cancer received an extreme degree of radiation toxicity. Further history revealed that the dose adjustment of a particular drug was missed during the course of radiotherapy. Which of the following drugs required a dose adjustment in that patient during radiotherapy to prevent radiation toxicity?

Dactinomycin. ***Dactinomycin*** - **Dactinomycin (Actinomycin D)** is known to potentiate radiation effects, meaning it can significantly increase the tissue damage from radiation. - When given concurrently with radiation or prior to radiation, its dose must be carefully adjusted or avoided to prevent severe radiation toxicity, including **radiation recall** phenomena. *Vincristine* - **Vincristine** is a vinca alkaloid primarily used for its antimitotic activity, interfering with microtubule formation. - While it has its own significant toxicities (e.g., neurotoxicity), it is not typically associated with directly potentiating radiation toxicity to the same extent as dactinomycin, nor does it commonly require dose adjustment due to radiation interaction to prevent severe toxicity of this nature. *Cyclophosphamide* - **Cyclophosphamide** is an alkylating agent often used in chemotherapy and immunosuppression. - Although it has various toxicities (e.g., hemorrhagic cystitis, myelosuppression), it is not specifically known for significantly enhancing radiation toxicity in a manner that necessitates routine dose adjustment during concurrent radiotherapy to prevent extreme local radiation effects. *6-Mercaptopurine* - **6-Mercaptopurine** is an antimetabolite primarily used in acute lymphoblastic leukemia. - It interferes with nucleic acid synthesis but is not typically highlighted as a drug that critically requires dose adjustment during radiotherapy to avoid extreme radiation potentiation or recall reactions.

Q: Which of the following statements about busulfan is false?

It can result in Addison's disease. ***It can result in Addison's disease*** - This statement is considered **false** in the context of traditional pharmacology teaching, though this requires clarification. - Busulfan causes **primary adrenocortical insufficiency** through direct cytotoxic damage to the adrenal cortex. - Traditionally, some sources reserve "Addison's disease" specifically for **autoimmune adrenalitis** (the most common cause), distinguishing it from other causes of primary adrenal insufficiency. - However, modern usage often considers **Addison's disease synonymous with primary adrenocortical insufficiency** of any etiology, including drug-induced. - For exam purposes, the distinction being tested is that busulfan causes **drug-induced adrenal toxicity**, not autoimmune destruction. *It can also cause veno occlusive disease of liver* - **TRUE** - Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a well-documented complication of busulfan. - This is particularly common in **high-dose conditioning regimens** before hematopoietic stem cell transplantation. - Results from direct damage to hepatic **sinusoidal endothelial cells**. *It is an alkylating anti neoplastic drug* - **TRUE** - Busulfan is a **bifunctional alkylating agent** that cross-links DNA. - Belongs to the alkyl sulfonate class of alkylating agents. - Used primarily in **chronic myeloid leukemia (CML)** and as a conditioning agent before bone marrow transplantation. *It can lead to pulmonary fibrosis* - **TRUE** - "**Busulfan lung**" is a characteristic and serious long-term toxicity. - Can develop months to years after treatment. - Presents with progressive dyspnea and restrictive lung disease pattern.

Q: An example of an IMiD (immunomodulatory derivative of thalidomide) is:

Lenalidomide. ***Lenalidomide*** - **Lenalidomide** is a well-known **immunomodulatory imide drug (IMiD)** derived from thalidomide, commonly used in the treatment of multiple myeloma and myelodysplastic syndromes. - IMiDs are characterized by their ability to modulate immune responses, enhance T-cell and NK-cell activity, and have direct anti-cancer effects through inhibition of angiogenesis and tumor cell proliferation. *Palivizumab* - **Palivizumab** is a **monoclonal antibody** that targets the fusion protein of respiratory syncytial virus (RSV), used for prophylaxis in high-risk infants. - It is not classified as an immunomodulatory imide drug and has a completely different structure and mechanism of action. *Ribavirin* - **Ribavirin** is an **antiviral agent** primarily used to treat chronic hepatitis C virus infection and respiratory syncytial virus. - Its mechanism of action is antiviral, not immunomodulatory in the same way as IMiDs. *None of the options* - This option is incorrect because **Lenalidomide** is indeed an example of an IMiD, making the statement false. - At least one correct answer exists among the given choices.

Q: Bleomycin toxicity affects which type of cells?

Type II pneumocytes. ***Type II pneumocytes*** - **Bleomycin** primarily causes lung toxicity by damaging **Type II pneumocytes**, leading to fibrosis. - These cells are more vulnerable due to their **lower concentrations of bleomycin hydrolase**, an enzyme that inactivates the drug. *Type I pneumocytes* - While **Type I pneumocytes** line most of the alveolar surface, they are less directly affected by bleomycin in the initial stages of toxicity compared to Type II cells. - Damage to Type I pneumocytes usually follows more severe and widespread lung injury. *Endothelial cells* - **Endothelial cells** play a role in vascular permeability and inflammation but are not the primary target of bleomycin toxicity in the lung. - Bleomycin's direct toxic effect is on the **alveolar epithelial cells**. *Pulmonary macrophages* - **Pulmonary macrophages** are immune cells involved in clearing debris and pathogens, and while they participate in the inflammatory response to bleomycin-induced lung injury, they are not the direct cellular target of the drug. - Their role is largely secondary to initial damage to **Type II pneumocytes**.

Q: What is the mechanism of action of Bevacizumab?

Anti VEGF antibody. ***Anti VEGF antibody*** - **Bevacizumab** is a **monoclonal antibody** that specifically targets and binds to vascular endothelial growth factor (VEGF). - By inhibiting VEGF, bevacizumab prevents the formation of new blood vessels (**angiogenesis**) that tumors need to grow and metastasize. *Histone deacetylase inhibitor* - **Histone deacetylase (HDAC) inhibitors** influence gene expression by modifying chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells. - They are used in certain hematologic malignancies and solid tumors but do not directly interfere with angiogenesis. *Proteasome inhibitor* - **Proteasome inhibitors** like bortezomib block the action of proteasomes, leading to an accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. - This mechanism is distinct from blocking new blood vessel formation. *HER2 neu inhibitor* - **HER2 neu inhibitors** (e.g., trastuzumab) specifically target the HER2/neu receptor, which is overexpressed in certain breast and gastric cancers. - Their action primarily involves blocking growth signals transmitted through this receptor, not inhibiting VEGF or angiogenesis.

Q: Characteristic toxicity of daunorubicin is

Cardiotoxicity. ***Cardiotoxicity*** - **Daunorubicin** is an **anthracycline antibiotic** commonly used in cancer chemotherapy. - Its most characteristic and dose-limiting toxicity is **cardiotoxicity**, which can manifest as dose-dependent reversible **myocardial dysfunction** or irreversible **congestive heart failure**. *Pulmonary toxicity* - While some chemotherapy agents can cause pulmonary toxicity (e.g., bleomycin, busulfan), it is **not a primary or characteristic toxicity of daunorubicin**. - Pulmonary fibrosis or pneumonitis is less commonly associated with anthracyclines compared to their cardiac effects. *Peripheral nerve damage* - **Peripheral neuropathy** is a common adverse effect of other chemotherapy drugs, such as **vincristine** or **cisplatin**. - It is **not a characteristic toxicity** associated with daunorubicin. *Bladder toxicity* - **Bladder toxicity**, particularly **hemorrhagic cystitis**, is characteristic of drugs like **cyclophosphamide** and **ifosfamide**. - This adverse effect is **not typical** of daunorubicin.

Q: Hand and foot syndrome can be caused by:

Capecitabine. ***Capecitabine*** - **Capecitabine** is a **prodrug** of 5-fluorouracil that is well-known for causing **hand-foot syndrome (palmar-plantar erythrodysesthesia)**. - This adverse effect is characterized by **erythema**, **swelling**, **pain**, and **desquamation** of the palms and soles. *Cisplatin* - **Cisplatin** is an **alkylating agent** primarily associated with **nephrotoxicity**, **ototoxicity**, and severe **nausea and vomiting**. - It is not a common cause of **hand-foot syndrome**. *Dactinomycin* - **Dactinomycin** (actinomycin D) is an **antibiotic chemotherapy agent** primarily associated with **myelosuppression**, **mucositis**, and **extravasation leading to tissue necrosis**. - While skin reactions can occur, **hand-foot syndrome** is not a characteristic side effect. *Vinblastine* - **Vinblastine** is a **vinca alkaloid** that inhibits microtubule formation, leading to **myelosuppression**, **peripheral neuropathy**, and **constipation**. - **Hand-foot syndrome** is not a typical adverse effect of vinblastine.

Question 1

Estramustine is a combination of which two drugs?

Accepted Answer

Estradiol + Normustine

Answer

Estradiol + mechlorethamine

Answer

Etoposide + Cisplatin

Answer

Tamoxifen + Letrozole

Question 2

Anticancer drug causing syndrome of inappropriate antidiuretic hormone secretion (SIADH) as an adverse effect is:

Accepted Answer

Vincristine

Answer

Paclitaxel

Answer

Dacarbazine

Answer

Cyclophosphamide

Question 3

A patient with cancer received an extreme degree of radiation toxicity. Further history revealed that the dose adjustment of a particular drug was missed during the course of radiotherapy. Which of the following drugs required a dose adjustment in that patient during radiotherapy to prevent radiation toxicity?

Accepted Answer

Dactinomycin

Answer

Vincristine

Answer

Cyclophosphamide

Answer

6-Mercaptopurine

Question 4

Which of the following statements about busulfan is false?

Accepted Answer

It can result in Addison's disease

Answer

It can also cause veno occlusive disease of liver

Answer

It is an alkylating anti neoplastic drug

Answer

It can lead to pulmonary fibrosis

Question 5

An example of an IMiD (immunomodulatory derivative of thalidomide) is:

Accepted Answer

Lenalidomide

Answer

Palivizumab

Answer

Ribavirin

Answer

None of the options

Question 6

Bleomycin toxicity affects which type of cells?

Accepted Answer

Type II pneumocytes

Answer

Type I pneumocytes

Answer

Endothelial cells

Answer

Pulmonary macrophages

Question 7

What is the mechanism of action of Bevacizumab?

Accepted Answer

Anti VEGF antibody

Answer

Histone deacetylase inhibitor

Answer

HER2 neu inhibitor

Answer

Proteasome inhibitor

Question 8

Characteristic toxicity of daunorubicin is

Accepted Answer

Cardiotoxicity

Answer

Pulmonary toxicity

Answer

Peripheral nerve damage

Answer

Bladder toxicity

Question 9

Hand and foot syndrome can be caused by:

Accepted Answer

Capecitabine

Answer

Cisplatin

Answer

Dactinomycin

Answer

Vinblastine

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?